Biotech Entrepreneur, CEO, Professor, Physician-Scientist, Therapeutics Designer & Developer
We are proud to share interim results from the Phase 1 stage of the AEROW clinical trial evaluating 4D-710, our aerosolized #geneticmedicine for treating #cysticfibrosis lung disease. These positive results give us confidence to move into Phase 2 and mark an important step forward in addressing CF and support the expanded use of our next-generation A101 pulmonary vector for other large-market lung diseases with significant unmet need. Thank you to the clinical investigators, the study participants and their families, the advocacy community, and the #4DMT team for their relentless engagement and support.
Today, we announced positive interim data from the Phase 1/2 AEROW clinical trial of aerosolized 4D-710 for the treatment of CFTR modulator-ineligible/-intolerant #cysticfibrosis (CF) lung disease. We will be hosting a webcast at 8 a.m. ET, to discuss the data and next steps for the program. Dr. Jennifer Taylor-Cousar M.D., #ClinicalTrial Principal Investigator, will present the data at #ECFS2024 later today. Find webcast details and the interim data results here: https://lnkd.in/ggN7bW8T
Keynote Speaker, Author, Professor, and Consultant
1moCongratulations! On to Phase 2!